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with elective support device insertion, especially in those performed in patients with
acute myocardial infarction in absence of shock.
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Background: The introduction of new medical devices may be accompanied by a
learning curve.
Methods: To evaluate the impact of the device learning curve on the outcomes of
PROTECT II trial, comparing Impella 2.5 versus the intra-aortic balloon pump (IABP)
during high-risk percutaneous coronary intervention, we report on additional analysis
excluding not only the ﬁrst Impella 2.5 and IABP patients at each site but also the ﬁrst
2 and ﬁrst 5 patients.
Results: A total of 448 patients were enrolled at 74 sites. Among these, 58 patients
were the ﬁrst to receive Impella 2.5 at their site, 62 were the ﬁrst to receive IABP.
After exclusion of the ﬁrst patient in each group, MAE rates for Impella 2.5 and IABP
were 38.0% versus 50.0% (p¼0.029) at 90 days. After excluding the ﬁrst 2 patients
the MAE rates wee 51.7% versus 37.1% and after excluding the ﬁrst 5 patients the
MAE rates were 57.1 versus 37.3%.
Conclusions: Signiﬁcantly lower 90-day MAE rates were observed with the use of
Impella 2.5 compared to the use of IABP after excluding the ﬁrst patient per group at
each site. When excluding more patients, the MAE rates change, however, it also
drastically reduces the numer of sites included in this analysis. This analysis suggests a
learning curve associated with initial introduction of the Impella 2.5. Clinical trials
should better address the training aspect of new devices, especially when compared
with more established devices.TCT-70
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Background: Use of intra-aortic balloon pump (IABP) in addition to extracorporeal
membrane oxygenation (ECMO) for treatment of cardiac failure has become routine in
many institutions. However, data is conﬂicting on whether IABP utilization leads to
any incremental clinical beneﬁt on top of ECMO support.
Methods: A systematic Medline search was performed for studies reporting on sur-
vival to hospital discharge for cardiogenic shock or cardiac arrest requiring ECMO
which also reported IABP outcomes. Survival to hospital discharge for patients who
received concurrent IABP was compared to those who did not. Outcomes in the in-
cremental use of IABP in acute myocardial infarction, postcardiotomy cardiogenic
shock, when placed prior to initiation of ECMO, and in its routine use at initiation of
ECMO were also analyzed.
Results: Sixteen studies were included in the main analysis encompassing 1,517
patients. The cumulative survival rate for patients on ECMO only was 256/683
(37.5%) compared with 294/834 (35.3%) for patients also supported with IABP.
The risk ratio for survival of 1.143 (0.973 – 1.343) favored IABP use but was not
statistically signiﬁcant p¼0.105. After removal of one extreme outlier on funnel
plot, the risk ratio for survival on reanalysis of 1,430 patients was 1.052 (0.886 –
1.249) p¼0.563. The risk ratios for survival for IABP use in acute myocardial
infarction and postcardiotomy cardiogenic shock were 1.120 (0.772 – 1.624)
p¼0.552 and 1.121 (0.826 – 1.520) p¼0.463, respectively. The risk ratios for
survival for IABP when placed prior to initiation of ECMO or as a routine
measure at the initiation of ECMO were 0.948 (0.718 – 1.252) p¼0.706 and
1.102 (0.806 – 1.506) p¼0.543, respectively. Funnel plot analysis suggested a
publication bias in favor of IABP use.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CardiogenConclusions: There was no survival beneﬁt observed with IABP use in addition to
ECMO only. Our analysis of existing literature does not provide support for routine
use of IABP in addition to ECMO. Further studies are needed to assess whether other
modalities of left ventricular venting such as percutaneous ventricular assist devices
add incremental beneﬁt to ECMO use.
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Background: TAVR is a novel procedure to treat high-risk or inoperable pa-
tients with severe symptomatic aortic stenosis. Randomized trials have excluded
TAVR for patients requiring urgent or emergent procedures or in circulatory
shock. The purpose of this study is to evaluate outcomes of urgent or emergent
TAVR in patients with circulatory shock secondary to severe aortic valve dis-
ease (AVD).
Methods: This retrospective case series included patients presenting to an aca-
demic hospital on inotropes and/or vasopressors who underwent TAVR for inop-
erable severe AVD. Data collection included morbidity, resource utilization, and
immediate procedural mortality (< 72 hours post procedure), 1-month, and
6-month all-cause mortality. Other outcomes collected were based on the stan-
dardized endpoint deﬁnitions for TAVR of the Valve Academic Research Con-
sortium-2 (VARC-2).
Results: The study cohort consisted of 11 consecutive patients in cardiogenic shock
with severe AVD. Most were men (10/11, 90.9%) and the median age was 75 years
(IQR 67-85). All patients were on either vasopressors or inotropes prior to the TAVR
procedure. The median Society of Thoracic Surgeons Score (STS) for predicted risk of
mortality was 32 (IQR: 23-53). There were no operative deaths. Only 1 patient of the
11 (9.1%) had an in-hospital mortality, while 10 (90.9%) survived to discharge. The
survival rate at 1 month was 91% (n¼10) and 72.7% (n¼8) at 3 and 6 months. The
rate of device success on initial deployment was 91% (n¼10) with 1 patient requiring
an emergent but successful TAVR-in-TAVR deployment. The median length of
hospital stay was 8 days (IQR 7-20). Other VARC-2 outcomes included: stroke (n¼0),
acute kidney injury (5/11, 45.5%), peri-procedural myocardial infarction (2/11,
18.2%), requirement of TAV-in-TAV deployment (1/11, 9.0%), conduction distur-
bances (n¼0).
Conclusions: In this retrospective, single-institution study, we demonstrate that
TAVR appears to be safe and feasible in selected high-risk or inoperable patients
with severe AVD and circulatory shock. Furthermore, a multi-institutional trial is
needed to evaluate the safety and feasibility of TAVR in this high-risk patient
population.
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Background: Cardiogenic shock (CS) occurs in up to 25% of patients with ST
elevation myocardial infarction (STEMI). Use of peripheral ventricular assist
device (p-VAD) such as intra aortic balloon pump (IABP) is recommended in
these patients. However, there is conﬂicting evidence regarding the timing of
initiation of IABP therapy in STEMI patients with CS. We aimed to determine
if there was a difference in outcomes between patients who had initiation of IABP
therapy in STEMI patients, pre- and post-percutaneous coronary intervention
(PCI).
Methods: Medical records of 613 consecutive patients undergoing primary PCI for
STEMI were screened to identify 174 patients receiving IABP therapy. Baseline
clinical and outcome data were compared between those receiving IABP pre (n¼76)
and post PCI (n¼98).
Results: Post-PCI IABP group had a higher association with ventricular arrhythmia
(p¼0.05), use of deﬁbrillation (p¼0.04), refractory shock (p¼0.05), cardiac arrest
during hospitalization (p¼0.05), and death at 1 year post index event (p¼ 0.05).
(Table 1) On logistic regression model using signiﬁcant baseline variables as cova-
riates, refractory shock retained its association with post-PCI IABP placement
(p¼0.005).
Conclusions: In patients with STEMI with CS, pre-PCI initiation of IABP therapy led
to fewer cases of refractory shock without affecting the door to balloon times, indi-
cating that early myocardial unloading improves overall clinical outcomes in STEMI
patients.ic Shock and Hemodynamic Support Devices B21
